Atom | Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis

Funder: Pfizer Inc.

Due Dates: May 13, 2026: Submission Deadline (full application) — applications due by 23:59 Eastern Standard Time (New York)

Funding Amounts: Up to $75,000 USD per project; total budget $150,000 USD; max project length 1 year

Summary: Supports educational initiatives that synthesize and communicate the safety data of JAK inhibitors for moderate-to-severe atopic dermatitis to healthcare providers.

Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis

Sign in to see full grant listing